Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 9,039 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pulmonary Clear all
Completed Phase 4 Interventional

Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes

NCT00280774
View directory record Official record
Conditions
Physiological Effects of Drugs
Interventions
Memantine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2008 · Synced Oct 30, 2026, 11:02 AM EDT
Active, not recruiting Not applicable Interventional

Testing the Engaged Approach to Lung Cancer Screening

NCT06327074
View directory record Official record
Conditions
Lung Cancer
Interventions
Engaged Approach to Lung Cancer Screening
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 30, 2026, 11:02 AM EDT
Active, not recruiting Not applicable Interventional

Exercise Rehabilitation in Veteran Cancer Survivors

NCT03621813
View directory record Official record
Conditions
Cancer
Interventions
Exercise Rehabilitation, Control
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 11:02 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Lung Nodule Sensitivity of Stationary Chest Tomosynthesis in Patients With Known Lung Nodules

NCT02075320
View directory record Official record
Conditions
Signs and Symptoms
Interventions
Stationary Digital Chest Tomosynthesis
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 30, 2026, 11:02 AM EDT
Completed Not applicable Interventional Results available

National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC

NCT03982459
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Decision support tool
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 30, 2026, 11:02 AM EDT
Terminated Phase 1 Interventional

Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal

NCT01341496
View directory record Official record
Conditions
Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancy
Interventions
Epigenetically Modified Autologous Tumor, Cyclophosphamide, Celecoxib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 30, 2026, 11:02 AM EDT
Completed No phase listed Observational

Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease

NCT02080897
View directory record Official record
Conditions
Soft Tissue Sarcoma, Metastatic Lung Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 30, 2026, 11:02 AM EDT
Recruiting Phase 2 Interventional

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

NCT07047690
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 30, 2026, 11:02 AM EDT
Completed Phase 1Phase 2 Interventional

IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

NCT04434482
View directory record Official record
Conditions
Advanced Solid Tumours, Small Cell Lung Cancer
Interventions
IMP4297(senaparib)
Drug
Lead sponsor
Impact Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Evergreen Park, Illinois • Canton, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 11:02 AM EDT
Terminated Phase 1Phase 2 Interventional

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

NCT01455389
View directory record Official record
Conditions
Lung Cancer
Interventions
DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone, Diphenhydramine
Drug
Lead sponsor
Genprex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 30, 2026, 11:02 AM EDT
Not listed No phase listed Observational

LungLB in Subjects Presenting With Indeterminate Pulmonary Nodules

NCT05171491
View directory record Official record
Conditions
Solitary Pulmonary Nodule, Multiple Pulmonary Nodules
Interventions
Not listed
Lead sponsor
LungLife AI
Industry
Eligibility
40 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Bay Pines, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 30, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Pilot and Feasibility Study of the Imaging Potential of EC17: Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA)

NCT01778920
View directory record Official record
Conditions
Lung and Pleural Malignancies, Neoplasms, Nodules, Adenocarcinoma
Interventions
EC17 imaging contrast agent
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 30, 2026, 11:02 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

NCT04655976
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Cobolimab, Dostarlimab, Docetaxel
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Fountain Valley, California • Walnut Creek, California • Norwich, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 30, 2026, 11:02 AM EDT
Completed No phase listed Observational

Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With IPF

NCT01874223
View directory record Official record
Conditions
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 30, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

NCT03752398
View directory record Official record
Conditions
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
Interventions
XmAb®23104, Yervoy® (ipilimumab)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 30, 2026, 11:02 AM EDT
Recruiting Phase 2 Interventional

Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

NCT04067830
View directory record Official record
Conditions
Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Best Practice, Laparoscopic Surgery, Quality-of-Life Assessment, Questionnaire Administration, Respiratory Muscle Training Device, Video-Assisted Thoracic Surgery
Other · Procedure · Device
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 30, 2026, 11:02 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
Interventions
LOXO-292
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
41
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 30, 2026, 11:02 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

NCT02393807
View directory record Official record
Conditions
Healthy
Interventions
PF 06260414 solid dose formulation, PF-06260414 nanosuspension
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 30, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia

NCT00336544
View directory record Official record
Conditions
Pneumonia
Interventions
Cethromycin, Clarithromycin
Drug
Lead sponsor
Advanced Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Woodridge, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 26, 2010 · Synced Oct 30, 2026, 11:02 AM EDT
Withdrawn Phase 2 Interventional

Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis

NCT01135199
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
pomalidomide (CC-4047
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 30, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

Pragmatic, Randomized Optimal Platelet and Plasma Ratios

NCT01545232
View directory record Official record
Conditions
Trauma
Interventions
1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
15 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 30, 2026, 11:02 AM EDT
Active, not recruiting Phase 1 Interventional

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

NCT04141644
View directory record Official record
Conditions
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
Interventions
Ipilimumab, Osimertinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 30, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

MK-3475 as Maintenance Therapy in Extensive Stage SCLC

NCT02359019
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma
Interventions
Pembrolizumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 30, 2026, 11:02 AM EDT
Completed Phase 2 Interventional

US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

NCT00515164
View directory record Official record
Conditions
Pulmonary Emphysema, Chronic Obstructive Pulmonary Disease
Interventions
Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel
Drug
Lead sponsor
Aeris Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Phoenix, Arizona • Iowa City, Iowa • Topeka, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Oct 30, 2026, 11:02 AM EDT